Summit Therapeutics SMMT Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Jazz PharmaceuticalsJAZZ

$123.1M+173%

InsmedINSM

$265.52M+230%

Vertex PharmaceuticalsVRTX

-$431.9M-674%

Roivant SciencesROIV

——

Gilead SciencesGILD

——

BiogenBIIB

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's cash provided by (used in) investing activity, including discontinued operation?: Summit Therapeutics (SMMT) reported cash provided by (used in) investing activity, including discontinued operation of -$238K in Q1 2026.
How has Summit Therapeutics's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?: Summit Therapeutics's cash provided by (used in) investing activity, including discontinued operation decreased by 100.1% year-over-year, from $160.11M to -$238K.